CG Oncology, Inc. (CGON) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-16

Key Insights

Insider Arthur Kuan, the CEO, has been granted a substantial stock option award of 271,600 shares, indicating strong management confidence in the company's future prospects.
The stock option award has a 10-year term and vests over 4 years, aligning Kuan's incentives with long-term shareholder value creation.
Kuan's direct ownership of the stock options suggests he is willing to tie his personal wealth to the company's performance, which can be viewed positively by investors.

Want the newest filings?

This analysis covers the filing from 2026-04-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-16

James DeTore, the Chief Financial Officer of CG Oncology, Inc., acquired 90,574 stock options with an exercise price of $67.68 and a vesting period of 4 years, indicating confidence in the company's future prospects.
The stock option grant suggests that CG Oncology is providing equity-based incentives to its executive team, which can align their interests with those of shareholders.
The timing of the stock option grant, shortly before the filing date, may indicate that the company is preparing for a potential catalyst or event that could impact the stock price.

Filed: 2026-04-16

Joshua F. Patterson, the General Counsel and Chief Compliance Officer, acquired 45,266 stock options in CG Oncology, Inc. (CGON) on April 15, 2026, with a strike price of $67.68 and a 10-year expiration date.
The options will vest over 4 years, with 1/48th of the shares vesting monthly, indicating a long-term commitment from the executive to the company.
Insider buying can signal management's confidence in the company's future prospects and growth potential.

Filed: 2026-04-16

Vijay Kasturi, the Chief Medical Officer of CG Oncology, Inc., has been granted 79,216 stock options with an exercise price of $67.68 and a vesting period of 4 years, indicating the company's commitment to retaining key leadership talent.
The option grant to Kasturi represents a significant increase in his ownership stake in the company, potentially aligning his interests with those of shareholders.
The timing of the option grant, in April 2026, suggests the company is making long-term investments in its management team and believes in the future growth potential of the business.

Filed: 2026-04-16

Ambaw Bellete, the President and COO of CG Oncology, Inc., has been granted 107,508 stock options with an exercise price of $67.68, vesting over 4 years.
This insider option grant suggests confidence in the company's future prospects and aligns Bellete's incentives with those of shareholders.
Investors should monitor Bellete's future trading activity and vesting of these options to gauge his ongoing commitment to the company.

Filed: 2026-03-17

Insider James Mulay, a director at CG Oncology, Inc. (CGON), exercised stock options and sold a total of 1,964 shares on March 16, 2026, indicating potential monetization of equity holdings.
The transactions were made pursuant to a pre-planned 10b5-1 trading plan, which suggests the sales were not driven by immediate concerns about the company's outlook.
Mulay still holds 1,964 shares after the reported transactions, maintaining a direct ownership stake in the company.

Filed: 2026-03-06

The CEO of CG Oncology, Arthur Kuan, has exercised stock options and acquired 100,000 shares of the company's common stock, indicating his confidence in the company's prospects.
Kuan has paid the exercise price for the options through a 'net exercise' transaction, where the company withheld a portion of the shares to cover the cost, suggesting he is interested in maintaining his equity stake in the company.
The timing of the transaction, which occurred on March 4, 2026, may signal that the CEO believes the company is well-positioned for future growth and development.

Filed: 2026-01-13

Insider James Mulay exercised stock options and sold a significant number of shares, indicating potential profit-taking or a change in his investment position.
The stock option exercises and sales were conducted pursuant to a pre-established 10b5-1 trading plan, suggesting a more systematic approach to managing his holdings.
The significant trading activity may signal changes in Mulay's outlook on the company or his desire to diversify his personal portfolio.

Other reports for CG Oncology, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.